title: Overall Survival in Patients with HER2+ Early Stage Breast Cancer Patients Treated with Trastuzumab in the US Department of Defense Practice Setting.
authors.affiliation: Walter Reed National Military Medical Center, Bethesda, MD, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Gallagher
authors.affiliation: Naval Medical Center Portsmouth, Portsmouth, VA, USA.
authors.forename: K
authors.initials: K
authors.lastname: More
authors.affiliation: Genentech, South San Francisco, CA, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Masaquel
authors.affiliation: Genentech, South San Francisco, CA, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kamath
authors.affiliation: Analysis Group, Inc., Montréal, QC, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Guerin
authors.affiliation: Analysis Group, Inc., Montréal, QC, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Ionescu-Ittu
authors.affiliation: Analysis Group, Inc., Montréal, QC, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Gauthier-Loiselle
authors.affiliation: Analysis Group, Inc., Montréal, QC, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Nitulescu
authors.affiliation: Health ResearchTx, Trevose, VA, USA.
authors.forename: N
authors.initials: N
authors.lastname: Sicignano
authors.affiliation: Genentech, South San Francisco, CA, USA.
authors.forename: B
authors.initials: B
authors.lastname: Barnett
authors.affiliation: Analysis Group, Inc., Boston, MA, USA.
authors.forename: E Q
authors.initials: EQ
authors.lastname: Wu